Danaher reports Q3 adjusted EPS $1.71, consensus $1.57

Reports Q3 revenue $5.8B, consensus $5.59B. Rainer Blair, president and CEO, stated, “Our team delivered strong third quarter results, including better-than-expected revenue growth. We were especially pleased with the continued positive momentum in our bioprocessing business and believe Cepheid gained market share in molecular testing again this quarter.”